MeiraGTx (MGTX) Expected to Announce Quarterly Earnings on Thursday

MeiraGTx (NASDAQ:MGTX) will likely be posting its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.46) per share and revenue of $6.95 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 20, 2026 at 12:30 PM ET.

MeiraGTx (NASDAQ:MGTX) last announced its quarterly earnings results on Thursday, August 13th. The company reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $2.17. The firm had revenue of $321.43 million during the quarter, compared to the consensus estimate of $0.70 million. MeiraGTx had a return on equity of 283.85% and a net margin of 19.87%. On average, analysts expect MeiraGTx to post $0.30 EPS for the current fiscal year and ($2.01) EPS for the next fiscal year.

MeiraGTx Stock Performance

Shares of MeiraGTx stock opened at $9.49 on Tuesday. The company has a quick ratio of 3.76, a current ratio of 3.76 and a debt-to-equity ratio of 0.46. MeiraGTx has a 52 week low of $6.62 and a 52 week high of $15.35. The firm’s 50 day moving average is $11.09 and its two-hundred day moving average is $10.34. The firm has a market capitalization of $911.42 million, a P/E ratio of 13.37 and a beta of 1.09.

Analyst Ratings Changes

Several brokerages have recently issued reports on MGTX. Wall Street Zen upgraded shares of MeiraGTx from a “hold” rating to a “buy” rating in a report on Saturday, October 24th. The Goldman Sachs Group started coverage on shares of MeiraGTx in a research note on Thursday, September 24th. They set a “neutral” rating and a $16.00 price target on the stock. Zacks Research lowered shares of MeiraGTx from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 11th. Weiss Ratings raised shares of MeiraGTx from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Finally, Royal Bank Of Canada upped their price objective on shares of MeiraGTx from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Friday, August 14th. Five equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, MeiraGTx presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

Insider Buying and Selling

In other MeiraGTx news, CFO Richard Giroux sold 56,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 20th. The stock was sold at an average price of $9.95, for a total value of $557,200.00. Following the completion of the sale, the chief financial officer owned 852,530 shares in the company, valued at approximately $8,482,673.50. The trade was a 6.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Stuart Naylor sold 27,659 shares of the stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $10.64, for a total value of $294,291.76. Following the completion of the sale, the insider directly owned 613,187 shares of the company’s stock, valued at $6,524,309.68. The trade was a 4.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 145,659 shares of company stock worth $1,710,812 in the last quarter. 7.40% of the stock is owned by insiders.

MeiraGTx Company Profile

MeiraGTx Holdings plc is a biotechnology company developing gene therapies for serious diseases with limited treatment options. Its research focuses on using adeno-associated virus (AAV) vectors to deliver genetic material to target cells, including in programs for inherited retinal diseases, neurological conditions and salivary gland dysfunction.

The company also develops manufacturing capabilities and technologies intended to support the production of gene therapies. MeiraGTx was founded in 2015 and has operations in the United States and the United Kingdom.